摘要

<正>1文献来源Wu Y, Zhou Q, Chen M, et al. LBA43-GEMSTONE-301:A randomized,double-blind,placebo-controlled,phase 3 study of sugemalimab in patients with unresectable stage Ⅲ non-small cell lung cancer(NSCLC)who had not progressed after concurrent or sequential chemoradiotherapy (CRT)[J]. Ann Oncol,2021,32(5S):S1283-S1346.

全文